RESUMO
The endocannabinoid system (ECS) plays a pivotal role in the complex control and regulation of food intake. Pharmacological ECS activation could improve health in energy-deficient stages by increasing food intake, at least in intermittent feeders. However, knowledge of the mechanism regulating appetite in species with continued nutrient delivery is incomplete. The objectives of this pilot study were to investigate the effect of the intraperitoneal (i.p.) administration of the endocannabinoids (ECs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG) on food intake, plasma EC concentrations and hypothalamic orexigenic signaling, and to study how the circulatory EC tone changes in response to short-term food deprivation in dairy cows, a species with continuous nutrient delivery. The administration of EC resulted in higher food intake during the first hour after treatment. Plasma AEA concentrations were significantly increased 2.5 h after AEA injection, whereas plasma 2-AG concentrations remained unchanged 2.5 h after 2-AG injection. The hypothalamic immunoreactivity of cannabinoid receptor 1, agouti-related protein, and orexin-A was not affected by either treatment; however, neuropeptide Y and agouti-related protein mRNA abundances were downregulated in the arcuate nucleus of AEA-treated animals. Short-term food deprivation increased plasma 2-AG, while plasma AEA remained unchanged. In conclusion, i.p.-administered 2-AG and AEA increase food intake in the short term, but only AEA accumulates in the circulation. However, plasma 2-AG concentrations are more responsive to food deprivation than AEA.
Assuntos
Ácidos Araquidônicos/metabolismo , Endocanabinoides/metabolismo , Comportamento Alimentar , Glicerídeos/metabolismo , Hipotálamo/metabolismo , Nutrientes , Orexinas/metabolismo , Alcamidas Poli-Insaturadas/metabolismo , Animais , Ácidos Araquidônicos/sangue , Peso Corporal , Bovinos , Endocanabinoides/sangue , Ácidos Graxos/metabolismo , Privação de Alimentos , Regulação da Expressão Gênica , Glucose/metabolismo , Glicerídeos/sangue , Leite , Alcamidas Poli-Insaturadas/sangue , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Transcrição GênicaRESUMO
Herbals that are widely consumed as therapeutic alternatives to conventional drugs for cardiovascular diseases, may lead to herb-drug interactions (HDIs). Atorvastatin (ATR) is drug of choice for hyperlipidemia and is extensively metabolized through CYP3A4 enzyme. Thus, we postulate that concomitant administration of ATR with piperine (PIP, potent inhibitor of CYP3A4 enzyme)/ridayarishta (RID, cardiotonic herbal formulations containing PIP) may lead to potential HDI. A simple, accurate, sensitive high-performance liquid chromatography-photodiode array detection method using Kromasil-100 C18 column, mobile phase acetonitrile: 30 mM phosphate buffer (55:45 v/v) pH 4.5 with flow rate gradient programming was developed to study the potential HDI in rats. Method was found to be linear (2-100 ng/mL) with Lower Limit of Detection (LLOD) 2 ng/mL. The precision (%CV < 15%), accuracy (-1.0 to -10% R.E) with recoveries above 90% from rat plasma of ATR and IS were obtained. The pharmacokinetic (PK) interactions studies on co-administration of ATR (8.4 mg/kg, p.o.) with PIP (35 mg/kg, p.o.), demonstrated a threefold increase in Cmax of ATR (P < 0.01) with significant increase in AUC0-t/AUC0-∞ compared to ATR alone indicating potential PK-HDI. However co-administration of RID (4.2 mL/kg, p.o.) showed less significant changes (P > 0.05) indicating low HDI. The pharmacodynamic effects/interactions study (TritonX-100 induced hyperlipidemic model in rats) suggested no significant alterations in the lipid profile on co-administration of PIP/RID with ATR, indicating that there may be no significant pharmacodynamic interactions.
Assuntos
Alcaloides , Atorvastatina , Benzodioxóis , Cromatografia Líquida de Alta Pressão/métodos , Piperidinas , Alcamidas Poli-Insaturadas , Alcaloides/sangue , Alcaloides/química , Alcaloides/farmacocinética , Animais , Atorvastatina/sangue , Atorvastatina/química , Atorvastatina/farmacocinética , Benzodioxóis/sangue , Benzodioxóis/química , Benzodioxóis/farmacocinética , Interações Ervas-Drogas , Limite de Detecção , Modelos Lineares , Piperidinas/sangue , Piperidinas/química , Piperidinas/farmacocinética , Extratos Vegetais/sangue , Extratos Vegetais/química , Extratos Vegetais/farmacocinética , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/química , Alcamidas Poli-Insaturadas/farmacocinética , Ratos , Ratos Wistar , Reprodutibilidade dos TestesRESUMO
BACKGROUND: Despite the importance of dairy proteins in modifying of metabolic abnormalities, no attention has been given to their effects on endocannabinoids. METHODS: A total number of 60 obese women were recruited in a 2-month randomized clinical trial. Following random allocation, they were assigned to one of the two groups: control (n = 30) and intervention (n = 30). Then, all the subjects followed a hypocaloric diet of 800 kcal below estimated energy needs. The intervention group received isocaloric weight-loss diet and whey protein powders (30 g/day). Baseline and 2-month fasting anthropometric, blood glucose, serum insulin, insulin resistance, lipid profile, AEA, and 2-AG were measured. RESULTS: The study groups were homogenous in terms of baseline characteristics (p > 0.05) except for MUFA intake (p = 0.021). There were no significant differences in energy and macronutrient intakes in the intervention group compared to the control group at the end of the study (p > 0.05). The results of the ANCOVA did not show significant reductions in body weight and BMI of the intervention group compared to the control group (p > 0.05); however, WC, body fat, FBS, AEA, 2-AG, total cholesterol, and triglyceride decreased and HDL-c significantly increased in the intervention group compared to the control group (p < 0.05). CONCLUSIONS: In this study, the effects of simultaneous weight-loss diet and whey protein supplementation on the reduction of endocannabinoids were determined. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT2017021410181N8 . Registered on March 2017.
Assuntos
Ácidos Araquidônicos/sangue , Dieta Redutora , Suplementos Nutricionais , Endocanabinoides/sangue , Obesidade/dietoterapia , Alcamidas Poli-Insaturadas/sangue , Redução de Peso , Proteínas do Soro do Leite/administração & dosagem , Adulto , Glicemia , Índice de Massa Corporal , Jejum , Feminino , Humanos , Insulina/sangue , Irã (Geográfico) , Lipídeos/sangue , Pré-MenopausaRESUMO
Increased levels of endocannabinoids, 2-arachidonoylglycerol (2-AG) and arachidonoyl ethanolamide (AEA) have a pathophysiological role in the setting of cardiometabolic diseases. This systematic review was carried out to appraise the effect of omega-3 on cardiometabolic risk factors by highlighting the mediating effect of endocannabinoids. SCOPUS, PubMed, Embase, Google Scholar and ProQuest databases were searched until January 2020. All published English-language animal studies and clinical trials that evaluated the effects of omega-3 on cardiometabolic diseases with a focus on endocannabinoids were included. Of 1407 studies, 16 animal studies and three clinical trials were included for analysis. Eleven animal studies and two human studies showed a marked reduction in 2-AG and AEA levels following intake of omega-3 which correlated with decreased adiposity, weight gain and improved glucose homeostasis. Moreover, endocannabinoids were elevated in three studies that replaced omega-3 with omega-6. Omega-3 showed anti-inflammatory properties due to reduced levels of inflammatory cytokines, regulation of T-cells function and increased levels of eicosapentaenoyl ethanolamide, docosahexaenoyl ethanolamide and oxylipins; however, a limited number of studies examined a correlation between inflammatory cytokines and endocannabinoids following omega-3 administration. In conclusion, omega-3 modulates endocannabinoid tone, which subsequently attenuates inflammation and cardiometabolic risk factors. However, further randomized clinical trials are needed before any recommendations are made to target the ECS using omega-3 as an alternative therapy to drugs for cardiometabolic disease improvement.
Assuntos
Anti-Inflamatórios/farmacologia , Doenças Cardiovasculares/metabolismo , Endocanabinoides/metabolismo , Ácidos Graxos Ômega-3/metabolismo , Animais , Ácidos Araquidônicos/sangue , Endocanabinoides/sangue , Glucose/metabolismo , Glicerídeos/sangue , Homeostase , Humanos , Inflamação , Oxilipinas/sangue , Oxilipinas/metabolismo , Fosfolipídeos/metabolismo , Alcamidas Poli-Insaturadas/sangue , Fatores de Risco , Transdução de SinaisRESUMO
BACKGROUND: Oxyresveratrol is a major bioactive component derived from the heartwood of Artocarpus lacucha. This compound exerts several biological activities, including neuroprotective effects in vitro and in vivo. However, there is limited pharmacokinetic information on this compound, especially its distribution in neuronal tissue and its route of excretion. The aim of this study was to investigate the pharmacokinetic profiles of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats. METHODS: Male Wistar rats were administered with oxyresveratrol 10 mg/kg, oxyresveratrol 10 mg/kg plus piperine 1 mg/kg via intravenous or oxyresveratrol 100 mg/kg, oxyresveratrol 100 mg/kg plus piperine 10 mg/kg via oral gavage. Plasma, internal organs, urine, and feces were collected. Determination of the oxyresveratrol concentration in biological samples was performed by liquid chromatography tandem mass spectrometry. RESULTS: The combination with piperine had shown a significantly higher maximum concentration in plasma approximately 1500 µg/L within 1-2 h after oral dosing, and could increase oral bioavailability of oxyresveratrol approximately 2-fold. Oxyresveratrol could widely distributed most of the internal organs with a tissue to plasma ratio of 10-100 fold within 5 min after dosing. Urinary excretion of oxyresveratrol glucuronide was the major route of excretion after administration of oxyresveratrol alone and in combination with piperine. CONCLUSION: The addition of piperine could enhance some of the pharmacokinetic properties of oxyresveratrol via both intravenous and oral administration. This pharmacokinetic information will be useful for appropriate strategies to develop oxyresveratrol as a phytopharmaceutical product.
Assuntos
Alcaloides , Benzodioxóis , Piperidinas , Extratos Vegetais , Alcamidas Poli-Insaturadas , Estilbenos , Administração Intravenosa , Administração Oral , Alcaloides/administração & dosagem , Alcaloides/sangue , Alcaloides/farmacocinética , Alcaloides/urina , Animais , Artocarpus , Benzodioxóis/administração & dosagem , Benzodioxóis/sangue , Benzodioxóis/farmacocinética , Benzodioxóis/urina , Interações Medicamentosas , Masculino , Piperidinas/administração & dosagem , Piperidinas/sangue , Piperidinas/farmacocinética , Piperidinas/urina , Extratos Vegetais/administração & dosagem , Extratos Vegetais/sangue , Extratos Vegetais/farmacocinética , Extratos Vegetais/urina , Alcamidas Poli-Insaturadas/administração & dosagem , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/farmacocinética , Alcamidas Poli-Insaturadas/urina , Ratos , Ratos Wistar , Estilbenos/administração & dosagem , Estilbenos/sangue , Estilbenos/farmacocinética , Estilbenos/urinaRESUMO
Uremia-associated anorexia may be related to altered levels of long chain n-6 and n-3 polyunsaturated fatty acid (PUFA) derived circulating endocannabinoids (EC) and EC-like compounds that are known to mediate appetite. Our study's hypothesis was that such molecules are associated with appetite in patients with end-stage renal disease. A cross-sectional observational study was performed in 20 chronic hemodialysis patients (9 females, 11 males) and 10 healthy female controls in whom appetite was assessed using the Simplified Nutritional Appetite Questionnaire (SNAQ) and blood drawn in the fasting (and when applicable) pre-dialysis state. Blood levels of PUFA and EC were also measured. Higher blood levels of the long chain n-6 fatty acid 20:4n6 (arachidonic acid) and lower levels of the long chain n-3 fatty acid 20:5n3 (eicosapentaenoic acid) were observed in female hemodialysis patients compared to controls. No differences were observed between male and female patients. In female study participants strong correlations between specific EC-like compounds and total SNAQ scores were noted, including with the n-6 PUFA derived linoleoyl ethanolamide (L-EA; ρ=-0.60, P<.01) and the n-3 PUFA derived docosahexaenoyl ethanolamide (DH-EA; ρ=0.63, P<.01). The L-EA:DH-EA ratio was most strongly associated with the SNAQ score (ρ=-0.74, P≤.001), and its questions associated with appetite (ρ=-0.69, P≤.01) and satiety (ρ=-0.81, P≤.001). These findings support a link between circulating EC and appetite in hemodialysis patients.
Assuntos
Apetite , Endocanabinoides/sangue , Diálise Renal , Adulto , Idoso , Estudos Transversais , Ácidos Graxos Ômega-3/sangue , Ácidos Graxos Ômega-6/sangue , Feminino , Humanos , Falência Renal Crônica/sangue , Falência Renal Crônica/terapia , Ácidos Linoleicos/sangue , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Alcamidas Poli-Insaturadas/sangue , Inquéritos e QuestionáriosRESUMO
Animal data suggest that dietary fat composition may influence endocannabinoid (EC) response and dietary behavior. This study tested the hypothesis that fatty acid composition of a meal can influence the short-term response of ECs and subsequent energy intake in humans. Fifteen volunteers on three occasions were randomly offered a meal containing 30 g of bread and 30 mL of one of three selected oils: sunflower oil (SO), high oleic sunflower oil (HOSO) and virgin olive oil (VOO). Plasma EC concentrations and appetite ratings over 2 h and energy intake over 24 h following the experimental meal were measured. Results showed that after HOSO and VOO consumption the circulating oleoylethanolamide (OEA) was significantly higher than after SO consumption; a concomitantly significant reduction of energy intake was found. For the first time the oleic acid content of a meal was demonstrated to increase the post-prandial response of circulating OEA and to reduce energy intake at subsequent meals in humans.
Assuntos
Regulação do Apetite , Desjejum , Endocanabinoides/sangue , Ingestão de Energia , Ácido Oleico/administração & dosagem , Ácidos Oleicos/sangue , Óleos de Plantas/química , Adulto , Amidas , Estudos Cross-Over , Registros de Dieta , Etanolaminas/sangue , Feminino , Humanos , Itália , Ácidos Linoleicos/sangue , Masculino , Ácido Oleico/análise , Azeite de Oliva , Ácidos Palmíticos/sangue , Alcamidas Poli-Insaturadas/sangue , Período Pós-Prandial , Óleo de Girassol , Adulto JovemRESUMO
N-Acylethanolamines (NAEs) are endogenous lipid-signaling molecules involved in satiety and energetics; however, how diet impacts circulating NAE concentrations and their downstream metabolic actions in humans remains unknown. Objectives were to examine effects of diets enriched with high-oleic canola oil (HOCO) or HOCO blended with flaxseed oil (FXCO), compared with a Western diet (WD), on plasma NAE levels and the association with energy expenditure and substrate oxidation. Using a randomized controlled crossover design, 36 hypercholesterolemic participants consumed three isoenergetic diets for 28 days, each containing 36% energy from fat, of which 70% was HOCO, FXCO, or WD. Ultra-performance liquid chromatography-MS/MS was used to measure plasma NAE levels and indirect calorimetry to assess energy expenditure and substrate oxidation. After 28 days, compared with WD, plasma oleoylethanolamide (OEA) and alpha-linolenoyl ethanolamide (ALEA) levels were significantly increased in response to HOCO and FXCO (P = 0.002, P < 0.001), respectively. Correlation analysis demonstrated an inverse association between plasma OEA levels and percent body fat (r = -0.21, P = 0.04), and a positive association was observed between the plasma arachidonoyl ethanolamide (AEA)/OEA ratio and android:gynoid fat (r = 0.23, P = 0.02), respectively. Results suggest that plasma NAE levels are upregulated via their dietary lipid substrates and may modulate regional and total fat mass through lipid-signaling mechanisms.
Assuntos
Adiposidade , Gorduras na Dieta/metabolismo , Endocanabinoides/sangue , Metabolismo Energético , Hipercolesterolemia/metabolismo , Ácidos Oleicos/sangue , Sobrepeso/fisiopatologia , Alcamidas Poli-Insaturadas/sangue , Regulação para Cima , Adulto , Índice de Massa Corporal , Estudos de Coortes , Estudos Cross-Over , Endocanabinoides/metabolismo , Ácidos Graxos Monoinsaturados/metabolismo , Feminino , Humanos , Hipercolesterolemia/sangue , Hipercolesterolemia/etiologia , Óleo de Semente do Linho/metabolismo , Masculino , Pessoa de Meia-Idade , Ácidos Oleicos/metabolismo , Oxirredução , Pacientes Desistentes do Tratamento , Alcamidas Poli-Insaturadas/metabolismo , Óleo de Brassica napus , Método Simples-CegoRESUMO
Previous research has shown that resveratrol can increase cerebral blood flow (CBF) in the absence of improved cognitive performance in healthy, young human subjects during the performance of cognitively demanding tasks. This lack of cognitive effects may be due to low bioavailability and, in turn, reduced bioefficacy of resveratrol in vivo. Piperine can alter polyphenol pharmacokinetics, but previous studies have not investigated whether this affects the efficacy of the target compound. Therefore, the objective of the present study was to ascertain whether co-supplementation of piperine with resveratrol affects the bioavailability and efficacy of resveratrol with regard to cognition and CBF. The present study utilised a randomised, double-blind, placebo-controlled, within-subjects design, where twenty-three adults were given placebo, trans-resveratrol (250 mg) and trans-resveratrol with 20 mg piperine on separate days at least a week apart. After a 40 min rest/absorption period, the participants performed a selection of cognitive tasks and CBF was assessed throughout the period, in the frontal cortex, using near-IR spectroscopy. The presence of resveratrol and its conjugates in the plasma was confirmed by liquid chromatography-MS analysis carried out following the administration of the same doses in a separate cohort (n 6). The results indicated that when co-supplemented, piperine and resveratrol significantly augmented CBF during task performance in comparison with placebo and resveratrol alone. Cognitive function, mood and blood pressure were not affected. The plasma concentrations of resveratrol and its metabolites were not significantly different between the treatments, which indicates that co-supplementation of piperine with resveratrol enhances the bioefficacy of resveratrol with regard to CBF effects, but not cognitive performance, and does this without altering bioavailability.
Assuntos
Alcaloides/metabolismo , Benzodioxóis/metabolismo , Circulação Cerebrovascular , Cognição , Suplementos Nutricionais , Lobo Frontal/irrigação sanguínea , Nootrópicos/metabolismo , Piperidinas/metabolismo , Alcamidas Poli-Insaturadas/metabolismo , Estilbenos/metabolismo , Adulto , Alcaloides/sangue , Alcaloides/uso terapêutico , Benzodioxóis/sangue , Benzodioxóis/uso terapêutico , Transtornos Cognitivos/sangue , Transtornos Cognitivos/metabolismo , Transtornos Cognitivos/prevenção & controle , Estudos de Coortes , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Absorção Intestinal , Masculino , Nootrópicos/agonistas , Nootrópicos/sangue , Nootrópicos/uso terapêutico , Projetos Piloto , Piperidinas/sangue , Piperidinas/uso terapêutico , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/uso terapêutico , Resveratrol , Espectroscopia de Luz Próxima ao Infravermelho , Estilbenos/agonistas , Estilbenos/sangue , Estilbenos/uso terapêutico , Análise e Desempenho de Tarefas , Adulto JovemRESUMO
Traditional Chinese Medicine (TCM) nasal therapy has been utilized to treat numerous diseases for over two millennia. It has many advantages compared with other routes. In this article, headspace-solid phase microextraction-gas chromatography-mass spectrometry and high performance liquid chromatography-atmospheric pressure chemical ionization-ion trap-time of flight-multistage mass spectrometry were applied for the first time to analyze the absorbed constituents in rabbit plasma and cerebrospinal fluid (CSF) after intranasal administration of Asari Radix et Rhizoma (AR). In total, 47 absorbed AR constituents including 14 monoterpenes, 10 phenylpropanoids, four benzene derivatives, two alkanes, nine N-alkylamides and eight lignans were tentatively identified in the rabbit plasma and CSF. Thirty-three absorbed constituents are found to have different bioactivities related to the pharmacological actions of AR through bibliography data retrieval. These indicated that many types of constituents of TCM can be absorbed at the nasal cavity into both rabbit blood and CSF. This is the first study to explore the absorption of AR, and comprehensively analyze the absorbed constituents after intranasal administration of TCM. These findings extend our understanding of the effective substances of AR, and inspire us to make a hypothesis on the mechanism of additive effect of multiple constituents of TCMs, which is very worthy of further investigation.
Assuntos
Magnoliaceae/química , Extratos Vegetais/farmacocinética , Rizoma/química , Administração Intranasal , Alcanos/sangue , Alcanos/líquido cefalorraquidiano , Animais , Derivados de Benzeno/sangue , Derivados de Benzeno/líquido cefalorraquidiano , Medicamentos de Ervas Chinesas , Lignanas/sangue , Lignanas/líquido cefalorraquidiano , Masculino , Monoterpenos/sangue , Monoterpenos/líquido cefalorraquidiano , Extratos Vegetais/sangue , Extratos Vegetais/líquido cefalorraquidiano , Extratos Vegetais/isolamento & purificação , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/líquido cefalorraquidiano , Propionatos/sangue , Propionatos/líquido cefalorraquidiano , CoelhosRESUMO
We have previously shown that treatment of Zucker rats and mice with diet-induced obesity with dietary docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids in the form of krill oil reduces peripheral levels of endocannabinoids, ectopic fat formation and hyperglycemia. We reported that such treatment reduces plasma endocannabinoid levels also in overweight and obese human individuals, in whom high triglycerides may correlate with high circulating endocannabinoid levels. In this study, we report the effects of krill powder, which contains proteins (34%) in addition to krill oil (61.8%), on these two parameters. We submitted 11 obese men (average BMI of 32.3 kg/m², age of 42.6 years and plasma triglycerides of 192.5 ± 96.3 mg/dl) to a 24 week dietary supplementation with krill powder (4 g/day per os) and measured anthropometric and metabolic parameters, as well as blood endocannabinoid (anandamide and 2-arachidonoylglycerol) and esterified DHA and EPA levels. Six subjects were included as control subjects and not given any supplements. The treatment produced, after 12 and 24 weeks, a significant increase in DHA and EPA in total plasma, a 59 and 84% decrease in anandamide plasma levels, and a 22.5 and 20.6% decrease in triglyceride levels, respectively. There was also a significant decrease in waist/hip ratio and visceral fat/skeletal muscle mass ratio at 24 weeks, but no change in body weight. These data confirm that dietary krill powder reduces peripheral endocannabinoid overactivity in obese subjects, and might ameliorate some parameters of the metabolic syndrome.
Assuntos
Euphausiacea/química , Obesidade/sangue , Obesidade/tratamento farmacológico , Pós/administração & dosagem , Adulto , Animais , Ácidos Araquidônicos/sangue , Suplementos Nutricionais , Endocanabinoides/sangue , Ácidos Graxos Ômega-3/metabolismo , Glicerídeos/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/patologia , Alcamidas Poli-Insaturadas/sangue , Pós/química , Triglicerídeos/sangue , Estados UnidosRESUMO
Alkylamides are a group of active components of the widely used herb Echinacea purpurea (E. purpurea), which have immunostimulatory and anti-inflammatory effects. For the most abundant alkylamides, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (DTAI), an LC-MS/MS assay has been developed and validated for quantification in human plasma. This assay will be used to support a clinical interaction study with E. purpurea. A 300 µL plasma aliquot underwent liquid-liquid extraction with diethylether-n-hexane (50:50, v/v). After evaporization and reconstitution in 100 µL of acetonitrile-water (50:50, v/v) 20 µL of sample were injected into the HPLC system. Chromatographic separation was achieved with a Polaris 3 C18-A column (50 mm × 2 mm ID, particle size 3 µm), a flow rate of 0.3 mL/min and isocratic elution with acetonitrile-water (50:50, v/v) containing 0.1% formic acid during the first 5 min. Hereafter, gradient elution was applied for 0.5 min, followed by restoration of the initial isocratic conditions. The total run time was 7.5 min. The assay was validated over a concentration range from 0.01 to 50 ng/mL for DTAI, with a lower limit of quantification of 0.01 ng/mL. Validation results show that DTAI can be accurately and precisely quantified in human plasma. DTAI also demonstrated to be chemically stable under relevant conditions. Finally, the applicability of this assay has been successfully demonstrated by measuring the plasma concentration of DTAI in patients after ingestion of a commercial extract of E. purpurea.
Assuntos
Cromatografia Líquida/métodos , Echinacea/química , Ácidos Graxos Insaturados/sangue , Alcamidas Poli-Insaturadas/sangue , Espectrometria de Massas em Tandem/métodos , Estabilidade de Medicamentos , Ácidos Graxos Insaturados/química , Ácidos Graxos Insaturados/farmacocinética , Humanos , Modelos Lineares , Extratos Vegetais/química , Alcamidas Poli-Insaturadas/química , Alcamidas Poli-Insaturadas/farmacocinética , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement. The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Assuntos
Antipsicóticos/uso terapêutico , Ácidos Araquidônicos/fisiologia , Canabidiol/uso terapêutico , Endocanabinoides/fisiologia , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Transdução de Sinais/efeitos dos fármacos , Sulpirida/análogos & derivados , Doença Aguda , Adulto , Amidas , Amissulprida , Ácidos Araquidônicos/sangue , Método Duplo-Cego , Quimioterapia Combinada , Endocanabinoides/sangue , Etanolaminas/sangue , Feminino , Humanos , Masculino , Ácidos Oleicos/sangue , Ácidos Palmíticos/sangue , Alcamidas Poli-Insaturadas/sangue , Escalas de Graduação Psiquiátrica , Esquizofrenia/fisiopatologia , Transdução de Sinais/fisiologia , Sulpirida/uso terapêutico , Adulto JovemRESUMO
The alkaloids from Piper longum L. showed protective effects on Parkinson's disease models in our previous study and piperine and piperlonguminine were the two main constituents in the alkaloids. The present study aimed at developing a rapid, sensitive, and accurate UFLC-ESI-MS/MS method and validating it for the simultaneous determination of piperine and piperlonguminine in rat plasma using terfenadine as the internal standard. The analytes and internal standard (IS) were extracted from rat plasma using a simple protein precipitation by adding methanol/acetonitrile (1:1, v/v). A Phenomenex Gemini 3 u C18 column (20 mm × 2.00 mm, 3 µm) was used to separate the analytes and IS using a gradient mode system with a mobile phase consisting of water with 0.1% formic acid (mobile phase A) and acetonitrile with 0.1% formic acid (mobile phase B) at a flow rate of 0.4 mL/min and an operating column temperature of 25°C. The total analytical run time was 4 min. The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with transitions at m/z 286.1-201.1 for piperine, m/z 274.0-201.1 for piperlonguminine, and m/z 472.4-436.4 for the IS. The calibration curves were both linear (r>0.995) over a concentration range of 1.0 to 1000 ng/mL; the lower limit of quantification (LLOQ) was 1.0 ng/mL for both piperine and piperlonguminine. The intra-day and inter-day precisions (RSD %) were <12.1%, accuracies ranged from 86.6 to 120%, and recoveries ranged from 90.4 to 108%. The analytes were proven stable in the short-term, long-term, and after three freeze-thaw cycles. The method was successfully applied to pharmacokinetic studies of piperine and piperlonguminine in rats after oral administration of alkaloids from P. longum L.
Assuntos
Alcaloides/farmacologia , Benzodioxóis/sangue , Cromatografia Líquida de Alta Pressão/métodos , Dioxolanos/sangue , Piper/química , Piperidinas/sangue , Alcamidas Poli-Insaturadas/sangue , Espectrometria de Massas em Tandem/métodos , Administração Oral , Alcaloides/administração & dosagem , Alcaloides/sangue , Alcaloides/farmacocinética , Animais , Benzodioxóis/administração & dosagem , Benzodioxóis/farmacocinética , Dioxolanos/administração & dosagem , Dioxolanos/farmacocinética , Estabilidade de Medicamentos , Análise dos Mínimos Quadrados , Masculino , Piperidinas/administração & dosagem , Piperidinas/farmacocinética , Extratos Vegetais/farmacologia , Alcamidas Poli-Insaturadas/administração & dosagem , Alcamidas Poli-Insaturadas/farmacocinética , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
BACKGROUND: Alcoholics report persistent alcohol craving that is heightened by cognitive cues, stressful situations, and abstinence. The role of endogenous cannabinoids in human alcohol craving--though long suspected--remains elusive. MATERIALS AND METHODS: We employed laboratory exposure to stress, alcohol cue, and neutral relaxed situations through guided imagery procedures to evoke alcohol desire and craving in healthy social drinkers (n = 11) and in treatment-engaged, recently abstinent alcoholic subjects (n = 12) and assessed alcohol craving, heart rate, and changes in circulating endocannabinoid levels. Subjective anxiety was also measured as a manipulation check for the procedures. RESULTS: In healthy social drinkers, alcohol cue imagery increased circulating levels of the endocannabinoid anandamide, whereas neutral and stress-related imagery had no such effect. Notably, baseline and response anandamide levels in these subjects were negatively and positively correlated with self-reported alcohol craving scores, respectively. Cue-induced increases in heart rate were also correlated with anandamide responses. By contrast, no imagery-induced anandamide mobilization was observed in alcoholics, whose baseline anandamide levels were markedly reduced compared to healthy drinkers and were uncorrelated to either alcohol craving or heart rate. CONCLUSIONS: The results suggest that plasma anandamide levels provide a marker of the desire for alcohol in social drinkers, which is suppressed in recently abstinent alcoholics.
Assuntos
Álcoois/metabolismo , Ácidos Araquidônicos/sangue , Alcamidas Poli-Insaturadas/sangue , Síndrome de Abstinência a Substâncias/sangue , Síndrome de Abstinência a Substâncias/psicologia , Adulto , Ansiedade/sangue , Ansiedade/etiologia , Sinais (Psicologia) , Endocanabinoides , Feminino , Frequência Cardíaca/fisiologia , Humanos , Imagens, Psicoterapia/métodos , Masculino , Pessoa de Meia-Idade , Medição da Dor , Estatística como Assunto , Síndrome de Abstinência a Substâncias/fisiopatologia , Fatores de TempoRESUMO
The relative bioavailability of the major alkamides, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides, from Echinacea purpurea phytotherapeutic lozenges at three different dose levels (0.07, 0.21 and 0.9 mg) was evaluated in a pharmacokinetic study in humans and the possible effects on the immunological system were measured. Alkamides were found to be rapidly absorbed and measurable in plasma 10 min after administration of 0.21 and 0.9 mg lozenges and remained detectable for 3h for the 0.21 mg lozenges and for more then 3h for the 0.9 mg lozenges; 0.07 mg lozenges were measurable 20 min after administration and remained detectable for only 2h after the administration. A significant dose-independent down-regulation of the pro-inflammatory cytokines IL-12p70, IL-8, IL-6, IL-10 and TNF was observed 24h after oral administration. The results of non-compartmental pharmacokinetic analysis revealed that a C(max) of (0.65+/-0.41 ng/ml) was reached at 32 min with the 0.07 mg lozenges, (1.00+/-0.21ng/ml) at 25 min with the 0.21 mg lozenges and (8.88+/-5.89 ng/ml) at 19 with the 0.9mg lozenges. As evidenced by the dose-exposure relationship, no significant departure from dose proportionality was observed, indicating linearity in pharmacokinetics. To get a further insight in pharmacokinetics of dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamides a compartmental population pharmacokinetic model was developed applying mixed effect modelling procedure. The results demonstrate that within the dose range studied pharmacokinetics of dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamides are linear and that absorption is very rapid (t(1/2)=6 min) with apparently no lag time, thus indicating the possibility that a fraction of the drug is absorbed through the oral mucosa.
Assuntos
Echinacea/química , Ácidos Graxos Insaturados/farmacologia , Ácidos Graxos Insaturados/farmacocinética , Extratos Vegetais/farmacologia , Extratos Vegetais/farmacocinética , Alcamidas Poli-Insaturadas/farmacologia , Alcamidas Poli-Insaturadas/farmacocinética , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/sangue , Adjuvantes Imunológicos/farmacocinética , Adjuvantes Imunológicos/farmacologia , Área Sob a Curva , Citocinas/sangue , Formas de Dosagem , Relação Dose-Resposta a Droga , Ácidos Graxos Insaturados/administração & dosagem , Ácidos Graxos Insaturados/sangue , Feminino , Meia-Vida , Humanos , Masculino , Fitoterapia , Extratos Vegetais/administração & dosagem , Extratos Vegetais/sangue , Alcamidas Poli-Insaturadas/administração & dosagem , Alcamidas Poli-Insaturadas/sangueRESUMO
Disturbances in the endogenous cannabinoid (ECB) system in schizophrenia may contribute to their enhanced sensitivity to psychoactive substances, and the beneficial effects of second-generation antipsychotics for substance abuse in schizophrenia may involve modulatory effects on ECB. To verify these two assumptions, 29 patients (24 completers) with schizophrenia and substance use disorders (SUD) were treated with quetiapine for 12 weeks, and peripheral ECB levels were measured, using high-performance liquid chromatography/mass spectrometry, in patients (weeks 0, 6 and 12) and 17 healthy volunteers. Baseline anandamide levels were significantly higher in patients, relative to controls. This result is consistent with studies describing ECB dysfunctions in schizophrenia. SUD parameters improved during treatment, but no changes in ECB occurred over time. Improvements in substance abuse were probably not mediated by modulatory effects of quetiapine on ECB. Lastly, baseline anandamide predicted endpoint SUD scores (alcohol/ cannabis). Anandamide is a potential target for medications aimed at relieving SUD in schizophrenia.
Assuntos
Antipsicóticos/uso terapêutico , Moduladores de Receptores de Canabinoides/sangue , Dibenzotiazepinas/uso terapêutico , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico , Adulto , Análise de Variância , Antipsicóticos/efeitos adversos , Ácidos Araquidônicos/sangue , Cromatografia Líquida de Alta Pressão , Diagnóstico Duplo (Psiquiatria) , Dibenzotiazepinas/efeitos adversos , Endocanabinoides , Feminino , Humanos , Modelos Lineares , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Alcamidas Poli-Insaturadas/sangue , Escalas de Graduação Psiquiátrica , Fumarato de Quetiapina , Psicologia do Esquizofrênico , Transtornos Relacionados ao Uso de Substâncias/psicologiaRESUMO
The aim of the present study was to investigate the short- and long-term effects of a high-fat Western diet (WD) on intake, storage, expenditure, and fecal loss of energy as well as effects on locomotor activity and thermogenesis. WD for only 24 h resulted in a marked physiological shift in energy homeostasis, including increased body weight gain, body fat, and energy expenditure (EE) but an acutely lowered locomotor activity. The acute reduction in locomotor activity was observed after only 3-5 h on WD. The energy intake and energy absorption were increased during the first 24 h, lower after 72 h, and normalized between 7 and 14 days on WD compared with mice given chow diet. Core body temperature and EE was increased between 48 and 72 h but normalized after 21 days on WD. These changes paralleled plasma T(3) levels and uncoupling protein-1 expression in brown adipose tissue. After 21 days of WD, energy intake and absorption, EE, and body temperature were normalized. In contrast, the locomotor activity was reduced and body weight gain was increased over the entire 21-day study period on WD. Calculations based on the correlation between locomotor activity and EE in 2-h intervals at days 21-23 indicated that a large portion of the higher body weight gain in the WD group could be attributed to the reduced locomotor activity. In summary, an acute and persisting decrease in locomotor activity is most important for the effect of WD on body weight gain and obesity in mice.
Assuntos
Dieta/efeitos adversos , Atividade Motora/fisiologia , Obesidade/etiologia , Animais , Ácidos Araquidônicos/sangue , Composição Corporal/fisiologia , Temperatura Corporal/fisiologia , Peso Corporal/fisiologia , Calorimetria Indireta , Colesterol na Dieta/efeitos adversos , DNA Complementar/biossíntese , DNA Complementar/genética , Gorduras Insaturadas na Dieta/efeitos adversos , Dopamina/metabolismo , Endocanabinoides , Ingestão de Energia/fisiologia , Metabolismo Energético/fisiologia , Ácidos Graxos/efeitos adversos , Fezes/química , Homeostase/fisiologia , Hormônios/sangue , Hipotálamo/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Obesidade/fisiopatologia , Alcamidas Poli-Insaturadas/sangue , RNA/biossíntese , RNA/genética , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
CONTEXT: Underlying mechanisms explaining the effects of osteopathic manipulative treatment (OMT) are poorly defined. The authors evaluate various nociceptive (pain) biomarkers that have been suggested as important mediators in this process. OBJECTIVE: To determine if OMT influences levels of circulatory pain biomarkers. METHODS: In a prospective, blinded assessment, blood was collected from 20 subjects (10 with chronic low back pain [LBP], 10 controls without chronic LBP) for 5 consecutive days. On day 4, OMT was administered to subjects 1 hour before blood collection. Blood was analyzed for levels of beta-endorphin (betaE), serotonin (5-hydroxytryptamine [5-HT]), 5-hydroxyindoleacetic acid (5-HIAA), anandamide (arachidonoylethanolamide [AEA]), and N-palmitoylethanolamide (PEA). A daily questionnaire was used to monitor confounding factors, including pain and stress levels, sleep patterns, and substance use. RESULTS: Increases from baseline in betaE and PEA levels and a decrease in AEA levels occurred immediately posttreatment. At 24 hours posttreatment, similar biomarker changes from baseline were observed. A decrease in stress occurred from baseline to day 5. The change in PEA from baseline to 24 hours posttreatment correlated with the corresponding changes in stress. Subgroup analysis showed that subjects with chronic LBP had significantly reduced 5-HIAA levels at 30 minutes posttreatment (P=.05) and 5-HT levels at 24 hours posttreatment (P=.02) when compared with baseline concentrations. The increase in PEA in subjects with chronic LBP at 30 minutes posttreatment was two times greater than the increase in control subjects. CONCLUSION: Concentrations of several circulatory pain biomarkers were altered after OMT. The degree and duration of these changes were greater in subjects with chronic LBP than in control subjects without the disorder.
Assuntos
Biomarcadores/sangue , Dor Lombar/sangue , Osteopatia/métodos , Adulto , Amidas , Ácidos Araquidônicos/sangue , Endocanabinoides , Etanolaminas , Feminino , Seguimentos , Humanos , Ácido Hidroxi-Indolacético/sangue , Dor Lombar/diagnóstico , Dor Lombar/terapia , Masculino , Pessoa de Meia-Idade , Medição da Dor , Ácidos Palmíticos/sangue , Projetos Piloto , Alcamidas Poli-Insaturadas/sangue , Estudos Prospectivos , Receptor CB2 de Canabinoide , Serotonina/sangue , Índice de Gravidade de Doença , Resultado do Tratamento , beta-Endorfina/sangueRESUMO
Alkamides are the major lipophilic constituents of ECHINACEA preparations, which are widely used in some European countries and in North America for common colds. In earlier investigations they have been shown to possess stimulatory effects on phagocytosis. Recent experiments have demonstrated that alkamides are detectable in human blood in relevant concentrations after oral administration of Echinacea preparations. Alkamides show structural similarity with anandamide, an endogenous ligand of cannabinoid receptors. Consequently, it was found that alkamides bind significantly to CB (2) receptors, which is now considered as a possible molecular mode of action of Echinacea alkamides as immunomodulatory agents. It was also demonstrated recently in several studies that alkamide-containing Echinacea preparations trigger effects on the pro-inflammatory cytokines. They were therefore suggested as a new class of cannabinomimetics. However, the therapeutic relevance of these findings is still not clear as clinical studies on the common cold show contradictory results. Among the many pharmacological properties reported, investigations concerning herb-drug interactions have been neglected for a long time. Latest research concludes that prolonged use of Echinacea poses a minimal risk for co-medications metabolized by the P450 enzymes.